EYEN News and Press, Eyenovia Inc. From 03/19/24

2024-03-19 12:48:26 ET More on Mid-day movers & stocks. Ontrak Health announces continuing expansion with Sentara Health Sarcos Technology and Robotics says co-founder Ben Wolff to become CEO Financial information for Aptorum Group Seeking Alpha’s ...

2024-03-19 10:00:51 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Johnson & Johnson, Boston...

2024-03-18 20:52:10 ET Eyenovia, Inc. (EYEN) Q4 2023 Earnings Conference Call March 18, 2024, 04:30 PM ET Company Participants Eric Ribner - IR Michael Rowe - Chief Executive Officer John Gandolfo - Chief Financial Officer Bren Kern - Chief Operating Officer ...

2024-03-18 16:13:58 ET More on Eyenovia Eyenovia: Racing Toward The Finish Line Eyenovia Q4 2023 Earnings Preview Eyenovia falls despite FDA nod for pain therapy Seeking Alpha’s Quant Rating on Eyenovia Historical earnings data for Eyenovia ...

Announced FDA approval of clobetasol propionate ophthalmic suspension 0.05% for post-operative pain and inflammation following ocular surgery Reacquired development and commercialization rights to MicroPine for progressive pediatric myopia in the U.S. and Canada Continued to adv...

Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31 Hongchang International Co Ltd Com (New) (HCIL) is expected to report for Q4 2023 BioStem Technologies Inc (BSEM) is expected to report $0.47 for Q4 2023 Nicox SA (NICXF) is expected to report $-0.07 for Q4 2023 ...

2024-03-17 08:20:00 ET Wall Street has reached a notable lull in the pace of quarterly releases. Still, investors are eagerly anticipating important announcements from FedEx ( NYSE: FDX ) and a set of prominent consumer brands, such as Nike ( NYSE: NKE ), Lululemon Athl...

EMERYVILLE, Calif. and NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN) announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare professionals across the U.S. Und...

NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic pharmaceutical technology company, today announced that the Company will release financial results for the fourth quarter ended December 31, 2023 on Monday, March 18 th , 2024, after ...

2024-03-05 13:34:43 ET More on Eyenovia Eyenovia: Racing Toward The Finish Line Upcoming FDA decision: Eyenovia’s (EYEN) APP13007 Seeking Alpha’s Quant Rating on Eyenovia Historical earnings data for Eyenovia Financial information for Ey...